Lumos Diagnostics Signals Turning Point In Earnings Call

Lumos Diagnostics Holdings Ltd. ((AU:LDX)) has held its Q2 earnings call. Read on for the main highlights of the call.

Lumos Diagnostics’ latest earnings call struck a cautiously upbeat tone as management highlighted a transformative U.S. distribution deal, accelerating product revenue, and sharply improved cash flows. Executives acknowledged that profitability and full commercial ramp still hinge on regulatory approvals and capacity expansion, but argued that recent milestones have materially de‑risked the growth story.

Major U.S. PHASE Deal Underpins Growth

Lumos secured a six‑year exclusive U.S. distribution agreement for its FebriDx test with PHASE Scientific, locking in a minimum of USD 317 million in sales over the contract term. PHASE has already paid a USD 1.0 million exclusivity fee, recognized in first‑half revenue, signaling tangible commitment ahead of full commercial activation.

CLIA Waiver Submission Positions FebriDx for Wider Use

The company completed its CLIA waiver study in August and has submitted the package to the U.S. FDA, with management indicating a decision is expected imminently. A positive waiver outcome, targeted for March, would open the door to broad in‑office deployment and dramatically enlarge the addressable U.S. market for FebriDx.

Medicare Reimbursement Strengthens Test Economics

Lumos has secured Medicare and Medicaid reimbursement for FebriDx at USD 41.38 per test, as set by CMS, with seven MACs agreeing to pay the full amount. This reimbursement framework should significantly improve economics for physicians and is viewed as a critical lever for accelerating adoption once the CLIA waiver is in place.

Product Revenue Doubles on FebriDx Momentum

First‑half revenue reached USD 6.1 million, with product revenue rising to USD 1.7 million from USD 0.8 million a year earlier, a gain of roughly 112.5%. Management attributed the surge primarily to FebriDx traction and expects the PHASE partnership and regulatory milestones to drive further product‑led growth over time.

Gross Margins Trend Higher on Mix Shift

Gross profit came in at USD 4.2 million, translating to a 68% gross margin, up one point year on year and 13 points versus two years ago. FebriDx margins are reported to be north of 60%, and the company highlighted that a mix shift away from lower‑margin lines is helping sustain this margin expansion.

Cash Flow Turns Positive with Nondilutive Support

Operating cash flow swung to a small positive USD 0.1 million from a USD 6.8 million outflow in the prior corresponding period, underscoring improved capital discipline. Lumos also drew USD 2.8 million from BARDA in the half and secured about USD 6.2 million for a pediatric trial, emphasizing its preference for nondilutive funding tools including grants and structured facilities.

EBITDA Loss Narrows but Profitability Still Ahead

Adjusted EBITDA loss improved to USD 1.4 million in the first half, a marked step up from the USD 4.2 million loss in the prior year’s comparable period. Management framed this as evidence of operating leverage emerging in the model, even as the company remains loss‑making and continues to invest heavily in trials and U.S. commercial build‑out.

Services Segment Remains Cash‑Positive Despite IP Drop

Services revenue totaled USD 4.4 million, supported by roughly 14 active projects and new contract wins such as Aptatek, and the segment remained cash‑flow positive. However, IP‑related revenue fell sharply to USD 1.0 million from USD 2.6 million, as timing and scope changes on the Hologic project shifted revenue recognition into future periods.

Pediatric Study to Extend FebriDx Market

The company has secured around USD 6.2 million in funding to conduct a pediatric trial aimed at extending the FebriDx label to patients aged 2 to 12. The study is expected to conclude by year‑end and, if successful, could expand the product’s addressable market by an estimated 20%, further enhancing the long‑term growth runway.

Operating Costs Rise to Support U.S. Scale‑Up

Operating expenses increased as Lumos funded the CLIA waiver and pediatric trials, boosted U.S. sales and marketing, hired additional staff, and absorbed higher U.S. medical insurance costs. While these investments weigh on near‑term profitability, management argued that grant support from BARDA and future PHASE volumes should help offset the burden over time.

Financing Headroom and Future Capacity Needs

The company drew USD 1.0 million from an investor loan facility, leaving USD 4.0 million undrawn to support operations and strategic initiatives. Management believes current manufacturing capacity can satisfy expected PHASE demand for the first two years but made clear that further capital investment will be required to scale production beyond that horizon.

Loss of Lower‑Margin ViraDx Affects Top Line Mix

Lumos noted a reduction in revenue linked to the discontinuation of lower‑margin ViraDx product sales, which has contributed to a changing revenue mix. While this weighs on headline revenue, the exit from lower‑margin lines is also helping lift overall profitability metrics by concentrating growth in higher‑margin FebriDx volumes.

Guidance Leans on CLIA Waiver and PHASE Ramp

Management reiterated that an imminent CLIA waiver decision is the key catalyst, as approval would activate the six‑year PHASE agreement with its USD 317 million minimum sales commitment and trigger a USD 5.0 million prepayment. Guidance underscored current metrics—USD 6.1 million in first‑half revenue, 68% gross margin, narrowed EBITDA loss, modestly positive operating cash flow, and BARDA‑funded pediatric work expected to enlarge the FebriDx market by roughly 20%.

Lumos’ earnings call painted a picture of a diagnostics company on the cusp of a major U.S. inflection, with regulatory and reimbursement groundwork largely in place and a sizeable distribution deal ready to scale. Investors must still weigh execution and financing risks, but the mix of improving margins, rising product revenue, and nondilutive funding leaves management sounding more confident about the path to sustainable growth.